Corcept Therapeutics Incorporated (NASDAQ:CORT) Forecasted to Earn FY2025 Earnings of $1.40 Per Share

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Research analysts at HC Wainwright reduced their FY2025 EPS estimates for Corcept Therapeutics in a research note issued to investors on Thursday, May 2nd. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will earn $1.40 per share for the year, down from their previous estimate of $1.44. HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $0.97 per share.

A number of other equities analysts also recently commented on CORT. Truist Financial lifted their target price on Corcept Therapeutics from $42.00 to $44.00 and gave the company a “buy” rating in a research note on Thursday, May 2nd. StockNews.com lowered Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $40.10.

Corcept Therapeutics Trading Down 2.2 %

Shares of CORT opened at $23.97 on Monday. Corcept Therapeutics has a 52 week low of $20.84 and a 52 week high of $34.28. The firm has a market cap of $2.50 billion, a price-to-earnings ratio of 22.61 and a beta of 0.50. The stock has a 50 day moving average of $23.99 and a 200-day moving average of $25.15.

Corcept Therapeutics (NASDAQ:CORT) last released its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.25 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $0.04. The business had revenue of $146.80 million during the quarter, compared to the consensus estimate of $141.19 million. Corcept Therapeutics had a net margin of 22.38% and a return on equity of 24.19%. The business’s quarterly revenue was up 38.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.14 earnings per share.

Institutional Trading of Corcept Therapeutics

Hedge funds have recently bought and sold shares of the stock. FNY Investment Advisers LLC acquired a new stake in shares of Corcept Therapeutics during the 4th quarter worth approximately $32,000. Gladius Capital Management LP acquired a new stake in Corcept Therapeutics during the fourth quarter worth $36,000. GAMMA Investing LLC boosted its stake in Corcept Therapeutics by 90.6% during the first quarter. GAMMA Investing LLC now owns 1,218 shares of the biotechnology company’s stock worth $31,000 after buying an additional 579 shares in the last quarter. Planned Solutions Inc. bought a new stake in Corcept Therapeutics in the 4th quarter valued at $45,000. Finally, Headlands Technologies LLC bought a new position in shares of Corcept Therapeutics during the 4th quarter worth about $47,000. 93.61% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Corcept Therapeutics news, CAO Joseph Douglas Lyon sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $26.00, for a total value of $26,000.00. Following the transaction, the chief accounting officer now owns 6,774 shares in the company, valued at approximately $176,124. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, CAO Joseph Douglas Lyon sold 1,000 shares of the stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $26.00, for a total value of $26,000.00. Following the transaction, the chief accounting officer now owns 6,774 shares in the company, valued at $176,124. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Sean Maduck sold 27,068 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.97, for a total transaction of $702,955.96. Following the completion of the sale, the insider now directly owns 74,455 shares of the company’s stock, valued at $1,933,596.35. The disclosure for this sale can be found here. In the last ninety days, insiders sold 92,413 shares of company stock valued at $2,352,176. Corporate insiders own 20.50% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.